Summary
Global Markets Direct’s, ‘Bionomics Ltd - Product Pipeline Review - 2016’, provides an overview of the Bionomics Ltd’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Bionomics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Bionomics Ltd
- The report provides overview of Bionomics Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Bionomics Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Bionomics Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Bionomics Ltd’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bionomics Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bionomics Ltd’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bionomics Ltd Snapshot 6
Bionomics Ltd Overview 6
Key Facts 6
Bionomics Ltd - Research and Development Overview 7
Key Therapeutic Areas 7
Bionomics Ltd - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Bionomics Ltd - Pipeline Products Glance 14
Bionomics Ltd - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Bionomics Ltd - Early Stage Pipeline Products 16
IND/CTA Filed Products/Combination Treatment Modalities 16
Preclinical Products/Combination Treatment Modalities 17
Bionomics Ltd - Drug Profiles 18
BL-011256 - Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
BNC-101 - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
BNC-105 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
BNC-164 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
BNC-210 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
BNC-420 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Drug for Dyskinesia - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Drug for Pain - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Drugs for Solid Tumors - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Drugs to Inhibit MELK for Solid Tumors - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Bionomics Ltd - Pipeline Analysis 39
Bionomics Ltd - Pipeline Products by Target 39
Bionomics Ltd - Pipeline Products by Route of Administration 40
Bionomics Ltd - Pipeline Products by Molecule Type 41
Bionomics Ltd - Pipeline Products by Mechanism of Action 42
Bionomics Ltd - Dormant Projects 43
Bionomics Ltd - Discontinued Pipeline Products 44
Discontinued Pipeline Product Profiles 44
Drug to Inhibit RET Kinase for Lung and Thyroid Cancer 44
Bionomics Ltd - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47
List of Tables
Bionomics Ltd, Key Facts 6
Bionomics Ltd - Pipeline by Indication, 2016 8
Bionomics Ltd - Pipeline by Stage of Development, 2016 10
Bionomics Ltd - Monotherapy Products in Pipeline, 2016 11
Bionomics Ltd - Out-Licensed Products in Pipeline, 2016 12
Bionomics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Bionomics Ltd - Phase II, 2016 14
Bionomics Ltd - Phase I, 2016 15
Bionomics Ltd - IND/CTA Filed, 2016 16
Bionomics Ltd - Preclinical, 2016 17
Bionomics Ltd - Pipeline by Target, 2016 39
Bionomics Ltd - Pipeline by Route of Administration, 2016 40
Bionomics Ltd - Pipeline by Molecule Type, 2016 41
Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016 42
Bionomics Ltd - Dormant Developmental Projects,2016 43
Bionomics Ltd - Discontinued Pipeline Products, 2016 44
Bionomics Ltd, Subsidiaries 45
List of Figures
Bionomics Ltd - Pipeline by Top 10 Indication, 2016 8
Bionomics Ltd - Pipeline by Stage of Development, 2016 10
Bionomics Ltd - Monotherapy Products in Pipeline, 2016 11
Bionomics Ltd - Pipeline by Target, 2016 39
Bionomics Ltd - Pipeline by Route of Administration, 2016 40
Bionomics Ltd - Pipeline by Molecule Type, 2016 41
Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016 42
